A detailed history of Ubs Asset Management Americas Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 472,244 shares of VKTX stock, worth $25.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
472,244
Previous 479,394 1.49%
Holding current value
$25.2 Million
Previous $25.4 Million 17.65%
% of portfolio
0.01%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $356,356 - $503,860
-7,150 Reduced 1.49%
472,244 $29.9 Million
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $5.87 Million - $9.93 Million
123,806 Added 34.82%
479,394 $25.4 Million
Q1 2024

May 15, 2024

SELL
$17.4 - $94.5 $2.08 Million - $11.3 Million
-119,525 Reduced 25.16%
355,588 $29.2 Million
Q4 2023

Feb 14, 2024

SELL
$9.24 - $19.64 $33,097 - $70,350
-3,582 Reduced 0.75%
475,113 $8.84 Million
Q3 2023

Nov 13, 2023

BUY
$10.92 - $16.0 $5.23 Million - $7.66 Million
478,695 New
478,695 $5.3 Million
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $234,545 - $350,150
-111,159 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$5.58 - $7.04 $100,825 - $127,205
-18,069 Reduced 13.98%
111,159 $698,000
Q2 2021

Aug 16, 2021

BUY
$5.19 - $6.73 $150,447 - $195,089
28,988 Added 28.92%
129,228 $774,000
Q1 2021

May 14, 2021

SELL
$5.74 - $9.67 $163,016 - $274,628
-28,400 Reduced 22.08%
100,240 $634,000
Q4 2020

Mar 01, 2021

BUY
$5.3 - $6.71 $299,450 - $379,115
56,500 Added 78.32%
128,640 $724,000
Q2 2020

Aug 14, 2020

SELL
$4.35 - $8.08 $63,175 - $117,345
-14,523 Reduced 16.76%
72,140 $520,000
Q1 2020

May 15, 2020

SELL
$3.45 - $7.95 $2,970 - $6,844
-861 Reduced 0.98%
86,663 $405,000
Q4 2019

Feb 14, 2020

BUY
$6.38 - $8.73 $39,823 - $54,492
6,242 Added 7.68%
87,524 $701,000
Q3 2019

Nov 14, 2019

BUY
$6.55 - $8.6 $102,631 - $134,753
15,669 Added 23.88%
81,282 $559,000
Q2 2019

Aug 15, 2019

BUY
$7.67 - $10.63 $140,775 - $195,103
18,354 Added 38.84%
65,613 $0
Q1 2019

May 14, 2019

BUY
$7.58 - $9.94 $155,079 - $203,362
20,459 Added 76.34%
47,259 $0
Q4 2018

Feb 13, 2019

BUY
$7.16 - $16.21 $191,888 - $434,428
26,800 New
26,800 $205,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.1B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.